Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol
Key facts
- Who runs it
- Dexiong Han
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 207 people, planned
- Started
- 1 Jul 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Electroacupuncture (Hans-100A, Nanjing Jisheng Medical Technology, China)
- Pharmacotherapy:① Pregabalin ( Lyrica™ ,Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets, Weicai (China) Pharmaceutical Co., Ltd, China)
- Streitberger Placebo Needle Set ( Asiamed )
- Record updated
- 9 July 2025
Who can take part
- Age
- 20 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Meet the diagnostic criteria for PHN
- Age between 20 and 80 years old
- Voluntarily participate in the trial and sign the informed consent form
Who cannot take part
- Presence of severe liver or kidney dysfunction, malignant tumors, or other serious diseases
- Presence of hematologic diseases or coagulation disorders
- Presence of mental illness or other cognitive impairments, unable to understand or unwilling to cooperate with the study requirements
- Pregnant or lactating women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Postherpetic neuralgia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators are conducting a clinical study with the following objectives: to evaluate the clinical efficacy of electroacupuncture combined with pregabalin in treating Postherpetic Neuralgia(PHN); to investigate the correlation between serum biomarker levels and pain symptoms;and to determine whether serum biomarkers can serve as prognostic indicators for PHN.
Read full original descriptionShow less
This study utilizes a randomized controlled trial design with assessor blinding. A total of 207 eligible PHN patients were randomly assigned to three groups in a 1:1:1 ratio: the electroacupuncture group, the pharmacotherapy group, and the sham acupuncture group. Comparative analyses of pain intensity and serum biomarker concentrations were conducted across these groups.
For the assessment of clinical outcomes, the investigators employed the following measures: the Numerical Rating Scale(NRS), the Hamilton Anxiety Scale(HAMA), the Hamilton Depression Scale(HAMD), the 36-Item Short Form Health Survey(SF-36), serum levels of substance P(SP)and Neuropeptide Y(NPY), and inflammatory markers(IL-10,TNF-α). These assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment.
The investigators anticipate that this clinical trial will enhance our understanding of the therapeutic efficacy and underlying mechanisms of acupuncture in managing PHN. It aims to elucidate the relationship between serum biomarkers and the clinical manifestations of PHN, as well as to explore their potential prognostic value in disease outcomes.
The 3 groups in the trial
- Electroacupuncture groupTreatment being tested
Acupoint prescription: The therapeutic protocol utilized Ashi points (localized to herpetic lesion areas) and Jiaji points (EX-B2, ipsilateral to affected dermatomes). Acupuncture procedure: For Ashi points, sterile disposable needles (0.25 mm diameter, 40 mm length) were inserted at a 15° angle to a depth of 15-20 mm, without deqi sensation or manual manipulation. For Jiaji points (EX-B2), needles (0.30 mm diameter, 50 mm length) were inserted perpendicularly to a depth of 40-45 mm, with twisting manipulation (90° rotation at 90 cycles/min) until patients felt soreness, numbness, or distension. Electroacupuncture was applied using the Hans-100A device, with dense-disperse wave mode (2/100 Hz) and intensity adjusted to patient tolerance, for 30 minutes. Pharmacological intervention: Identical to the pharmacotherapy group.
Treatment: Electroacupuncture (Hans-100A, Nanjing Jisheng Medical Technology, China) and Pharmacotherapy:① Pregabalin ( Lyrica™ ,Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets, Weicai (China) Pharmaceutical Co., Ltd, China)
- Pharmacotherapy groupExisting treatment, for comparison
In accordance with the Interpretation of the expert consensus on the whole-process management of herpes zoster-associated pain, patients received protocol-guided therapy consisting of: ① Pregabalin: Initial dose 75 mg twice daily. Dose may be titrated upward to 150 mg twice daily within one week based on therapeutic response and tolerability. Gradual discontinuation is recommended when clinically appropriate, tapered by 100 mg decrements every 3-7 days. ② Mecobalamin tablets: 5 mg three times daily.
Treatment: Pharmacotherapy:① Pregabalin ( Lyrica™ ,Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets, Weicai (China) Pharmaceutical Co., Ltd, China)
- Sham acupuncture groupSham treatment, for comparison
Acupoint prescription: Identical to the electroacupuncture group. Acupuncture procedure: The Streitberger needle, a widely reported placebo needle device in acupuncture RCTs, was applied for sham intervention. Blinding assessments have predominantly demonstrated successful masking outcomes. This telescoping blunt-tip needle achieves non-penetrating placebo stimulation through its retractable design. Its key advantage lies in evoking a skin-penetrating sensation akin to true needling through tissue compression, while avoiding actual dermal perforation to minimize specific therapeutic effects. Following the perception of needle insertion reported by patients, the device is retracted by approximately 1 mm and connected to electroacupuncture apparatus without electrical stimulation activation. Pharmacological intervention: Identical to the pharmacotherapy group.
Treatment: Pharmacotherapy:① Pregabalin ( Lyrica™ ,Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets, Weicai (China) Pharmaceutical Co., Ltd, China) and Streitberger Placebo Needle Set ( Asiamed )
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06990854, who can take part
- Publications
- Record updated
- 9 July 2025